display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/adv melanoma (mML)
mML - L2 - all population
anti-CTLA-4
ipilimumab based treatment
ipilimumab alone MDX010 Ipi vs gp100
Ipilimumab (10 mg/kg) Ascierto ... CA184-004
ipilimumab plus gp100 MDX010 Ipi plus gp100 vs gp100 MDX010 Ipi plus gp100 vs Ipi ...
ipilimumab plus SoC CA184-024

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons